title: Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
abstract: Oleoylethanolamine (OEA), an endogenous high-affinity agonist of peroxisome proliferator-activated receptor alpha (PPAR-α), has revealed the pharmacological properties in the treatment of obesity, atherosclerosis and other diseases through the modulation of lipid metabolism. To assess whether OEA can also regulate non-alcoholic fatty liver disease (NAFLD) caused by fat accumulation, we administrated OEA or fenofibrate in Sprague Dawley (SD) rats fed with a high fat diet (HFD). After 6 or 17 weeks treatment, OEA (5 mg/kg/day, i.p.) relieved the development of NAFLD compared with control groups by regulating the levels of plasma TG, TC, ALT and AST and liver inflammatory cytokines. Gene expression analysis of liver tissue and plasma from the animal models showed that OEA and fenofibrate both promoted the lipid β-oxidation by activating PPAR-α. Detailed research revealed that OEA inhibited the mRNA expression of lipogenesis in a PPAR-α-independant manner, while fenofibrate expressed an opposite effection. In summary, our research results suggested that as a potential lead compound, OEA could improve HFD-induced NAFLD with higher efficacy and safety than fenofibrate.
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China; Department of Chemistry, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian, China.
authors.forename: Long
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Chen
authors.affiliation: Center of Liver Diseases, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China.
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Lin
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China.
authors.forename: Yaping
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ren
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Fu
authors.affiliation: Department of Medical Sciences, Medical College, Xiamen University, Xiamen, Fujian, China. Electronic address: yanqiu@xmu.edu.cn.
authors.forename: Yan
authors.initials: Y
authors.lastname: Qiu
mesh_terms: D000818:Animals; D059305:Diet, High-Fat / Q000009:adverse effects*; D063388:Endocannabinoids / Q000494:pharmacology* / Q000627:therapeutic use*; D005227:Fatty Acids / Q000378:metabolism; D011345:Fenofibrate / Q000494:pharmacology / Q000627:therapeutic use; D056945:Hep G2 Cells; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism / Q000187:drug effects; D050155:Lipogenesis / Q000187:drug effects / Q000235:genetics; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism*; D009829:Oleic Acids / Q000494:pharmacology* / Q000627:therapeutic use*; D010084:Oxidation-Reduction / Q000187:drug effects; D047493:PPAR alpha / Q000819:agonists*; D012333:RNA, Messenger / Q000378:metabolism; D017207:Rats, Sprague-Dawley
chemical_list: D063388:Endocannabinoids; D005227:Fatty Acids; D000960:Hypolipidemic Agents; D009829:Oleic Acids; D047493:PPAR alpha; D012333:RNA, Messenger; C488250:oleoylethanolamide; D011345:Fenofibrate
keywords: Fenofibrate; Lipid metabolism gene; Nonalcoholic fatty liver disease; Oleoylethanolamide; Peroxisome proliferator-activated receptor alpha